Jiangsu HengRui Medicine Co., Ltd. clinical trial failures

Review 35 stopped clinical trials from Jiangsu HengRui Medicine Co., Ltd., including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 0 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials35

Likely biological signals0

Shown below35

Dominant stop reasons

OTHER/UNKNOWN: 30
OPERATIONAL: 5

Notable sponsors

Jiangsu HengRui Medicine Co., Ltd.: 35

Related phases

Phase II: 15
Phase I: 10
Phase III: 10

Crawlable stopped-trial records

Open Explore

Showing up to 35 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT05009290: A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Phase III Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Due to the adjustment of the sponsor's development plan, after discussion with leading PI, sponsor has decided to terminate this study.

NCT06035393: A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase II Chronic Obstructive Pulmonary Disease trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor's R\&D strategy adjusted.

NCT04619433: A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Phase III Non-squamous Non-small-cell Lung Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OPERATIONAL.

Terminated by Sponsor

NCT05208177: A Study of SHR-1802 in Patients With Advanced Solid Tumor

Phase II Advanced Solid Tumor trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Adjustment of R\&D strategy

NCT06254742: A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Phase III Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

The sponsor's R\&D strategy is adjusted.

NCT04571710: A Trial of SHR1258 in Patients With Biliary Tract Cancer

Phase II Biliary Tract Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

The sponsor's R\&D strategy is adjusted.

NCT05983146: Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies

Phase I Advanced Malignant Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

The sponsor's R\&D strategy is adjusted.

NCT03777124: Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase II NSCLC Stage IV trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

The sponsor's R\&D strategy is adjusted.

NCT05470075: A Study to Evaluate the Efficacy and Safety of HR18042 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.

Phase II Pain trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

The sponsor's R\&D strategy is adjusted.

NCT04102124: A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Phase II Prostate Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

The sponsor's R\&D strategy is adjusted.

NCT05394402: A Trial of SHR0410 Injection in Postsurgical Pain Management

Phase II Postsurgical Pain trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Adjustment of R\&D strategy

NCT05799183: A SHR-1210 BE Study on Healthy Subjects

Phase I Advanced Tumors trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor's R\&D Strategy adjusted

NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Phase I Advanced Malignancies trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R\&D strategy adjustment

NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Phase III Metastatic Pancreatic Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT03711279: A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Phase II Sarcoma trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT04409223: Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Phase III Gastrointestinal Stromal Tumors trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

R\&D strategy adjustment

NCT04842630: A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Phase I Unspecified Adult Solid Tumor, Protocol Specific trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

R\&d strategy adjustment

NCT05261646: A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Phase III Chemotherapy-Induced Thrombocytopenia trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT05106335: A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Phase III Advanced NSCLC trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT05103826: A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

Phase I ER+ / HER2- Advanced Breast Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT04699968: A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Phase II Non-Small-Cell Lung Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT03871855: A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Phase I Advanced Solid Tumor trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT04335006: A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase III Breast Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT04985136: A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase III Advanced Hepatocellular Carcinoma (HCC) trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT03182673: The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase I Solid Tumor trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT03596658: SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Phase I ER+ HER2- Advanced Breast Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Sponsor R \& D Strategy Adjustment

NCT04479904: A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Phase II Intrahepatic Cholangiocarcinoma trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

It is difficult to screening subject

NCT03722186: Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Phase I Physiological Effects of Drugs trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OPERATIONAL.

Business Decision

NCT03666728: A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Phase II Lung Neoplasms trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

changes in the R\&D strategy

NCT03741712: A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Phase I Prostate Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

According to the available data from the trial，the sponsor determined to terminate this study.

NCT04121143: A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults

Phase II Plaque Psoriasis trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OPERATIONAL.

sponsor's decision

NCT02356991: A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Phase II Non-Small Cell Lung Cancer (NSCLC) trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

sponsor decides to suspend this trial

NCT03645876: SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Phase II Metastatic Colorectal Cancer trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OPERATIONAL.

The study was terminated early due to company decision

NCT01994213: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Phase II Gastroenteropancreatic Neuroendocrine Tumor trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OTHER/UNKNOWN.

The applicant decided to close the study

NCT02766140: SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Phase III Non Squamous Non Small Cell Lung trial by Jiangsu HengRui Medicine Co., Ltd.. Stop reason: OPERATIONAL.

difficulty in recruitment